Exelixis (EXEL): Analyst Upgrades and Value Signals Put Stock’s Valuation in Focus

Simply Wall St.

Oct 12

Exelixis (EXEL) recently caught attention after analysts raised earnings estimates and highlighted the stock's strong valuation metrics. This shift in sentiment has put Exelixis on the radar for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574029467"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574029467\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574029467?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2025-10-12 07:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574029467","market":"us","top_or_hot":-1,"title":"Exelixis (EXEL): Analyst Upgrades and Value Signals Put Stock’s Valuation in Focus","media":"Simply Wall St.","content":"<div>\n<p>Exelixis (EXEL) recently caught attention after analysts raised earnings estimates and highlighted the stock's strong valuation metrics. This shift in sentiment has put Exelixis on the radar for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-analyst-upgrades-and-value-signals-put-stocks\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis (EXEL): Analyst Upgrades and Value Signals Put Stock’s Valuation in Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis (EXEL): Analyst Upgrades and Value Signals Put Stock’s Valuation in Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-12 07:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-analyst-upgrades-and-value-signals-put-stocks><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exelixis (EXEL) recently caught attention after analysts raised earnings estimates and highlighted the stock's strong valuation metrics. This shift in sentiment has put Exelixis on the radar for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-analyst-upgrades-and-value-signals-put-stocks\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-analyst-upgrades-and-value-signals-put-stocks","article_id":"2574029467","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/exelixis-exel-analyst-upgrades-and-value-signals-put-stocks","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2574029467","pubTimestamp":1760224636,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Exelixis (EXEL) recently caught attention after analysts raised earnings estimates and highlighted the stock's strong valuation metrics. This shift in sentiment has put Exelixis on the radar for investors watching value and momentum plays.\nSee our latest analysis for Exelixis.\n\nExelixis has seen its share price rally 12.4% so far this year, while the one-year total shareholder return stands at an impressive 45.4%. This momentum has largely been fueled by earnings upgrades and persistent value...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"Exelixis(EXEL)：分析师升级和价值信号使股票估值成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.5},"content_text":"Exelixis (EXEL) recently caught attention after analysts raised earnings estimates and highlighted the stock's strong valuation metrics. This shift in sentiment has put Exelixis on the radar for investors watching value and momentum plays. See our latest analysis for Exelixis.  Exelixis has seen its share price rally 12.4% so far this year, while the one-year total shareholder return stands at an impressive 45.4%. This momentum has largely been fueled by earnings upgrades and persistent value signals. With analysts sounding increasingly positive and the valuation remaining attractive, growth potential appears to be building, not fading.\n  If Exelixis’s run has you curious about other promising healthcare names, take the next step and discover See the full list for free..   With analysts growing bullish and value metrics looking strong, the key question is whether Exelixis remains undervalued or if recent gains mean the stock has already priced in its growth prospects. Is there a buying opportunity, or is the market one step ahead?\n AdvertisementMost Popular Narrative: 13.4% Undervalued Exelixis’s most popular valuation narrative sees its fair value at $44.06 compared to a recent close of $38.15, suggesting room for upside if projections play out. This viewpoint sets up a sweeping case for continued investor optimism, driven by both the company’s pipeline and expansion playbook.  The recent introduction and rapid uptake of CABOMETYX in neuroendocrine tumors, combined with its continued strength and market leadership in renal cell carcinoma, signals an expanding patient base in tumor types with high unmet need. This is poised to drive strong durable revenue growth as aging populations and rising cancer incidence increase long-term demand for oncology therapeutics.  Read the complete narrative.  Curious what makes this valuation stand out? The narrative hinges on bold financial forecasts for future revenues, margins, and earnings, along with a crucial assumption about where the share count is headed. Want to see what those projections are and why they matter so much? Follow along to see the exact growth blueprint that justifies the fair value.\n Result: Fair Value of $44.06 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent reliance on Cabometyx and the threat of rising competition could significantly impact Exelixis's future earnings trajectory and valuation outlook. Find out about the key risks to this Exelixis narrative.  Build Your Own Exelixis Narrative If you want to dig deeper or challenge these perspectives, you can explore the numbers and shape your own take in just a few minutes. Do it your way. A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Exelixis. Looking for more investment ideas? If you want to stay a step ahead of the crowd, don’t let these unique stock opportunities pass you by. Each one is built to match a focused strategy and can help you make your next smart move.  Earn more passive income by tapping into proven yields with these 19 dividend stocks with yields > 3%, offering strong payouts and stability in changing markets. Ride the boom in artificial intelligence and uncover growth stories through these 24 AI penny stocks, which are defining tomorrow’s tech landscape. Seize untapped value by using these 899 undervalued stocks based on cash flows to pinpoint stocks trading below their intrinsic worth before the rest of the market catches on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}